Dr. Dorff on Current Agents for Patients With mCRPC

Tanya B. Dorff, MD
Published: Thursday, Nov 16, 2017



Tanya B. Dorff, MD, associate professor of clinical medicine, University of Southern California, discusses current agents available for patients with metastatic castration-resistant prostate cancer (mCRPC).

There are several agents available to treat patients with mCRPC, such as abiraterone acetate (Zytiga), enzalutamide (Xtandi), and docetaxel. However, patients treated with upfront intensification complicates the treatment process, says Dorff.

Novel agents, such as immunotherapy and PARP inhibitors, are being compared to these older agents in clinical trials, explains Dorff.


Tanya B. Dorff, MD, associate professor of clinical medicine, University of Southern California, discusses current agents available for patients with metastatic castration-resistant prostate cancer (mCRPC).

There are several agents available to treat patients with mCRPC, such as abiraterone acetate (Zytiga), enzalutamide (Xtandi), and docetaxel. However, patients treated with upfront intensification complicates the treatment process, says Dorff.

Novel agents, such as immunotherapy and PARP inhibitors, are being compared to these older agents in clinical trials, explains Dorff.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Management of Adverse Events Associated with Therapies for Hematological Disorders: Nurses' PerspectiveApr 21, 20182.0
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Publication Bottom Border
Border Publication
x